Orally Administered Rapamycin, Dacarbazine or Both for Treatment of Human Melanoma Evaluated in Severe Combined Immunodeficiency Mice

Publisher： Karger

E-ISSN： 1423-0313|82|3|233-238

ISSN： 0031-7012

Source： Pharmacology, Vol.82, Iss.3, 2008-09, pp. : 233-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma

By  

Chemotherapy, Vol. 55, Iss. 4, 2009-05 ,pp. : 221-227

Karger

Access to resources Recommend Favorite

Newborn Screening for Severe Combined Immunodeficiency in Israel

By Rechavi Erez   Lev Atar   Saraf-Levy Talia   Etzioni Amos   Almashanu Shlomo   Somech Raz  

International Journal of Neonatal Screening, Vol. 3, Iss. 2, 2017-06 ,pp. : 13-13

MDPI

Access to resources Recommend Favorite

Factors that Influence the Immunological Adjuvant Effect of Lactobacillus fermentum PC1 on Specific Immune Responses in Mice to Orally Administered Antigens

By Esvaran Meera   Conway Patricia L.  

Vaccines, Vol. 4, Iss. 3, 2016-07 ,pp. : 24-24

MDPI

Access to resources Recommend Favorite

Newborn Screening for Severe Combined Immunodeficiency in the US: Current Status and Approach to Management

By Dorsey Morna   Puck Jennifer  

International Journal of Neonatal Screening, Vol. 3, Iss. 2, 2017-06 ,pp. : 15-15

MDPI

Access to resources Recommend Favorite

Newborn Screening for Severe Combined Immunodeficiency-A History of the TREC Assay

By Bausch-Jurken Mary T.   Verbsky James W.   Routes John M.  

International Journal of Neonatal Screening, Vol. 3, Iss. 2, 2017-06 ,pp. : 14-14

MDPI

Access to resources Recommend Favorite